Literature DB >> 15231628

Making decisions about benefits and harms of medicines.

Trisha Greenhalgh1, Olga Kostopoulou, Clare Harries.   

Abstract

Keywords:  Health Care and Public Health

Mesh：

Year:  2004        PMID： 15231628      PMCID： PMC443458          DOI： 10.1136/bmj.329.7456.47

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

Review 1.  New concerns about thalidomide.

Authors:  Beau M Ances
Journal:  Obstet Gynecol       Date:  2002-01       Impact factor: 7.661

2.  Pharmacogenetics--expectations and reality.

Authors:  Geoff Tucker
Journal:  BMJ       Date:  2004-07-03

3.  Informed choice and balance are victims of the MMR-autism saga.

Authors:  Tom Jefferson
Journal:  Lancet Infect Dis       Date:  2004-03       Impact factor: 25.071

4.  Why do doctors use treatments that do not work?

Authors:  Jenny Doust; Chris Del Mar
Journal:  BMJ       Date:  2004-02-28

5.  Development of the Clozaril Patient Management System.

Authors:  B Bastani; L D Alphs; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  The total customer relationship in health care: broadening the bandwidth.

Authors:  D M Berwick
Journal:  Jt Comm J Qual Improv       Date:  1997-05

Review 7.  Presenting risk information--a review of the effects of "framing" and other manipulations on patient outcomes.

Authors:  A Edwards; G Elwyn; J Covey; E Matthews; R Pill
Journal:  J Health Commun       Date:  2001 Jan-Mar

Review 8.  The extent of patients' understanding of the risk of treatments.

Authors:  A J Lloyd
Journal:  Qual Health Care       Date:  2001-09

Review 9.  Alosetron and irritable bowel syndrome.

Authors:  Emeran A Mayer; Sylvie Bradesi
Journal:  Expert Opin Pharmacother       Date:  2003-11       Impact factor: 3.889

Review 10.  Patient choice and complementary medicine.

Authors:  E Ernst
Journal:  J R Soc Med       Date:  2004-01       Impact factor: 18.000
  10 in total
  8 in total

1.  Over-the-counter medicines.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

2.  Balancing benefits and harms in health care: ethical dimension was not discussed in theme issue.

Authors:  Richard E Ashcroft
Journal:  BMJ       Date:  2004-08-21

Review 3.  A strategy for regulatory action when new adverse effects of a licensed product emerge.

Authors:  Jeffrey K Aronson; Deirdre Price; Robin E Ferner
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

4.  Social Media and COVID-19-Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics.

Authors:  Natalie Schellack; Morné Strydom; Michael S Pepper; Candice L Herd; Candice Laverne Hendricks; Elmien Bronkhorst; Johanna C Meyer; Neelaveni Padayachee; Varsha Bangalee; Ilse Truter; Andrea Antonio Ellero; Thulisa Myaka; Elysha Naidoo; Brian Godman
Journal:  Antibiotics (Basel)       Date:  2022-03-25

5.  Is There a Tension between Clinical Practice and Reimbursement Policy? The Case of Osteoarthritis Prescribing Practices in Ontario.

Authors:  Parminder S Raina; Amiram Gafni; Sandra Bell; Susan Grant; Rolf J Sebaldt; Aimei Fan; Annie Petrie; Kevin Skilton
Journal:  Healthc Policy       Date:  2007-11

6.  Homeless drug users' awareness and risk perception of peer "take home naloxone" use--a qualitative study.

Authors:  Nat Wright; Nicola Oldham; Katharine Francis; Lesley Jones
Journal:  Subst Abuse Treat Prev Policy       Date:  2006-10-02

7.  Evaluation of adverse drug reaction formatting in drug information mobile phone applications.

Authors:  Sean M McConachie; Dena Berri; Jewel Konja; Christopher A Giuliano
Journal:  J Med Libr Assoc       Date:  2022-01-01

8.  Adverse drug reactions in drug information databases: does presentation affect interpretation?

Authors:  Sean M McConachie; Christopher A Giuliano; Insaf Mohammad; Pramodini B Kale-Pradhan
Journal:  J Med Libr Assoc       Date:  2020-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.